# Tracon Pharmaceuticals Inc. clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Tracon Pharmaceuticals Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Tracon Pharmaceuticals Inc.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/tracon-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 7, 2022 | NCT05448820 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | Tracon Pharmaceuticals Inc. | Phase 1/2 | Unknown | Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05448820) |
| July 21, 2020 | NCT04480502 | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma | Tracon Pharmaceuticals Inc. | Phase 2 | Unknown | Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04480502) |
| February 11, 2019 | NCT03835949 | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | Tracon Pharmaceuticals Inc. | Phase 1 | Unknown | Solid Tumor, Metastatic Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03835949) |
| December 19, 2018 | NCT03780010 | Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC | Tracon Pharmaceuticals Inc. | Phase 1 | Completed | Non Small Cell Lung Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03780010) |
| June 8, 2017 | NCT03181308 | Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | Tracon Pharmaceuticals Inc. | Phase 1 | Completed | Carcinoma, Non-Small-Cell Lung | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03181308) |
| December 9, 2016 | NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | Tracon Pharmaceuticals Inc. | Phase 1/2 | Completed | Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02987829) |
| December 2, 2016 | NCT02979899 | Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma | Tracon Pharmaceuticals Inc. | Phase 3 | Completed | Advanced Angiosarcoma | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02979899) |
| January 27, 2016 | NCT02664961 | Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) | Tracon Pharmaceuticals Inc. | Phase 2 | Terminated | Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic... | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02664961) |
| September 25, 2015 | NCT02560779 | Trial of TRC105 and Sorafenib in Patients With HCC | Tracon Pharmaceuticals Inc. | Phase 1/2 | Completed | Hepatocellular Carcinoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02560779) |
| March 24, 2015 | NCT02396511 | TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma | Tracon Pharmaceuticals Inc. | Phase 2 | Completed | Choriocarcinoma | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02396511) |
| February 3, 2015 | NCT02354612 | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | Tracon Pharmaceuticals Inc. | Not applicable | No longer available | Solid Tumors | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02354612) |
| November 4, 2013 | NCT01975519 | A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue... | Tracon Pharmaceuticals Inc. | Phase 1/2 | Completed | Advanced Soft Tissue Sarcoma | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01975519) |
| March 7, 2013 | NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | Tracon Pharmaceuticals Inc. | Phase 1/2 | Terminated | Renal Cell Carcinoma | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01806064) |
| March 28, 2012 | NCT01564914 | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma | Tracon Pharmaceuticals Inc. | Phase 2 | Completed | Glioblastoma, Glioblastoma Multiforme | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01564914) |
| June 27, 2011 | NCT01381861 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | Tracon Pharmaceuticals Inc. | Phase 2 | Completed | Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01381861) |
| April 11, 2011 | NCT01332721 | Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | Tracon Pharmaceuticals Inc. | Phase 1 | Completed | Adult Solid Tumor | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01332721) |
| March 31, 2011 | NCT01326481 | Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer | Tracon Pharmaceuticals Inc. | Phase 1/2 | Completed | Metastatic Breast Cancer | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01326481) |
| June 6, 2008 | NCT00692159 | Study of TRC102 in Combination With Pemetrexed in Cancer Patients | Tracon Pharmaceuticals Inc. | Phase 1 | Completed | Neoplasm | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00692159) |
| December 28, 2007 | NCT00582985 | Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer | Tracon Pharmaceuticals Inc. | Phase 1 | Completed | Cancer, Neoplasm Metastasis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00582985) |
| June 27, 2007 | NCT00492830 | Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors | Tracon Pharmaceuticals Inc. | Phase 1 | Completed | Cancer, Neoplasm Metastasis | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00492830) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 6 |
| Phase 2 | 5 |
| Phase 3 | 1 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Unknown | 3 |
| Terminated | 2 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Sarcoma | 3 |
| Hemangiosarcoma | 2 |
| Choriocarcinoma | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 1 |
| Chondrosarcoma | 1 |
| Neoplastic Processes | 1 |
| Pathologic Processes | 1 |
| Pathological Conditions, Signs and Symptoms | 1 |
| Histiocytoma, Malignant Fibrous | 1 |
| Dermatofibrosarcoma | 1 |
| Adenocarcinoma | 1 |
| Carcinoma, Renal Cell | 1 |
| Glioblastoma | 1 |
| Gestational Trophoblastic Disease | 1 |
| Trophoblastic Tumor, Placental Site | 1 |
| Ovarian Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Uniform stores in the United States](https://specstream.ai/data/businesses/uniform-stores/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
